MENU
+Compare
ADAP
Stock ticker: NASDAQ
AS OF
Sep 5 closing price
Price
$0.04
Change
-$0.01 (-20.00%)
Capitalization
13.52M

ADAP Adaptimmune Therapeutics plc Forecast, Technical & Fundamental Analysis

Adaptimmune Therapeutics PLC is a commercial-stage biopharmaceutical company working to redefine the treatment of solid tumor cancers with cell therapies... Show more

Industry: #Biotechnology
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I.Advisor
a Summary for ADAP with price predictions
Sep 05, 2025

ADAP in -22.05% downward trend, declining for three consecutive days on September 05, 2025

Moving lower for three straight days is viewed as a bearish sign. Keep an eye on this stock for future declines. Considering data from situations where ADAP declined for three days, in of 341 cases, the price declined further within the following month. The odds of a continued downward trend are .

Price Prediction Chart

Technical Analysis (Indicators)

Bearish Trend Analysis

The Aroon Indicator for ADAP entered a downward trend on August 29, 2025. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Bullish Trend Analysis

The RSI Indicator entered the oversold zone -- be on the watch for ADAP's price rising or consolidating in the future. That's also the time to consider buying the stock or exploring call options.

The Stochastic Oscillator demonstrated that the ticker has stayed in the oversold zone for 2 days, which means it's wise to expect a price bounce in the near future.

The Moving Average Convergence Divergence (MACD) for ADAP just turned positive on August 19, 2025. Looking at past instances where ADAP's MACD turned positive, the stock continued to rise in of 48 cases over the following month. The odds of a continued upward trend are .

Following a +1 3-day Advance, the price is estimated to grow further. Considering data from situations where ADAP advanced for three days, in of 219 cases, the price rose further within the following month. The odds of a continued upward trend are .

ADAP may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Fundamental Analysis (Ratings)

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is fair valued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: P/B Ratio (5.921) is normal, around the industry mean (20.107). P/E Ratio (0.000) is within average values for comparable stocks, (52.767). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (2.138). Dividend Yield (0.000) settles around the average of (0.043) among similar stocks. P/S Ratio (0.202) is also within normal values, averaging (327.388).

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating slightly worse than average price growth. ADAP’s price grows at a lower rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating that the returns do not compensate for the risks. ADAP’s unstable profits reported over time resulted in significant Drawdowns within these last five years. A stable profit reduces stock drawdown and volatility. The average Profit vs. Risk Rating rating for the industry is 95, placing this stock worse than average.

View a ticker or compare two or three
ADAP
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interact to see
Advertisement
A.I. Advisor
published Earnings

ADAP is expected to report earnings to rise 110.00% to -4 cents per share on November 05

Adaptimmune Therapeutics plc ADAP Stock Earnings Reports
Q3'25
Est.
$-0.04
Q2'25
Beat
by $0.03
Q1'25
Beat
by $0.09
Q4'24
Missed
by $0.02
Q3'24
Est.
$-0.01
The last earnings report on August 13 showed earnings per share of -1 cents, beating the estimate of -5 cents. With 35.23M shares outstanding, the current market capitalization sits at 13.52M.
A.I. Advisor
published General Information

General Information

a manufacturer of vaccines and cancer immunotherapy products

Industry Biotechnology

Profile
Fundamentals
Details
Industry
Biotechnology
Address
60 Jubilee Avenue
Phone
+44 1235430000
Employees
449
Web
https://www.adaptimmune.com
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
YOUL2.000.13
+6.68%
Youlife Group Inc.
HOUS6.460.25
+4.03%
Anywhere Real Estate
IRM92.181.10
+1.21%
Iron Mountain
CXT61.10-0.62
-1.00%
Crane NXT Co
NXTC4.85-0.09
-1.82%
NextCure Inc

ADAP and Stocks

Correlation & Price change

A.I.dvisor indicates that over the last year, ADAP has been loosely correlated with NEVPF. These tickers have moved in lockstep 56% of the time. This A.I.-generated data suggests there is some statistical probability that if ADAP jumps, then NEVPF could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To ADAP
1D Price
Change %
ADAP100%
-19.61%
NEVPF - ADAP
56%
Loosely correlated
N/A
AKBA - ADAP
41%
Loosely correlated
-1.99%
ORMP - ADAP
36%
Loosely correlated
+0.45%
CSLLY - ADAP
32%
Poorly correlated
-0.58%
AXON - ADAP
31%
Poorly correlated
-0.24%
More